Annemieke Aartsma-Rus

This inventor holds 12 USPTO granted patents and 17 published patent applications, plus 11 CIPO patents and 14 EPO patents. Top assignees: Academisch Ziekenhuis Leiden, Biomarin Technologies B.v., Academisch Ziekenhuis Leiden (h.o.d.n. Lumc). Active years: 2013-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Annemieke Aartsma-Rus. Retrieved from https://idiyas.com/inventor/annemieke-aartsma-rus

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 12 (Patent Applications = 17)

% Patents Active = 83.3

CIPO Patents = 11 (Patent Applications = 5)

EPO Patents = 14 (Patent Applications = 16)

Average Co-Inventor Count = 4.6

ph-index = 7

Forward Citations = 338(Granted Patents)

Location History:

BE Hoofddorp, NL (2015)
Leiden, NL (2018)
Hoofddorp, NL (2013 - 2021)

Company Filing History:

9 out of 47

Academisch Ziekenhuis Leiden

patents

4 out of 16

Biomarin Technologies B.v.

patents

3 out of 43

Academisch Ziekenhuis Leiden (h.o.d.n. Lumc)

patents

4. 2 out of 4

Prosensa Technologies B.v.

patents

where one patent can have more than one assignee

Years Active: 2013-2021

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. RE48468 - Means and methods for counteracting muscle disorders (2021-03-15),

2. 10590421 - Antisense oligonucleotide directed removal of proteolytic cleavage sites, the HCHWA-D mutation, and trinucleotide repeat expansions (2020-03-17),

3. 10364432 - Antisense oligonucleotide directed removal of proteolytic cleavage sites from proteins (2019-07-30),

4. 10246707 - Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means (2019-04-02),

5. 10113165 - Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure (2018-10-30),

6. 9926557 - Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA (2018-03-27),

7. 9896687 - Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure (2018-02-20),

8. 9611471 - Antisense oligonucleotide directed removal of proteolytic cleavage sites from proteins (2017-04-04),

9. 9243245 - Means and methods for counteracting muscle disorders (2016-01-26),

10. 9139828 - Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means (2015-09-22),

11. 8802645 - Molecule for treating an inflammatory disorder (2014-08-12),

12. 8361979 - Means and method for inducing exon-skipping (2013-01-29),

Title: Annemieke Aartsma-Rus: Innovator in Muscle Disorder Therapies

Introduction

Annemieke Aartsma-Rus is a prominent inventor based in Hoofddorp, Netherlands. She has made significant contributions to the field of medical research, particularly in developing therapies for muscle disorders. With a total of 12 patents to her name, her work focuses on innovative solutions for conditions such as Duchenne Muscular Dystrophy and Becker Muscular Dystrophy.

Latest Patents

Among her latest patents is a groundbreaking invention titled "Means and methods for counteracting muscle disorders." This invention provides methods for alleviating symptoms associated with Duchenne Muscular Dystrophy and Becker Muscular Dystrophy. The therapy combines compounds that provide patients with functional muscle proteins along with adjunct compounds aimed at reducing inflammation and improving muscle fiber function. Another notable patent is "Antisense oligonucleotide directed removal of proteolytic cleavage sites, the HCHWA-D mutation, and trinucleotide repeat expansions." This patent describes methods for removing specific mutations from proteins, enhancing the potential for effective treatments.

Career Highlights

Annemieke has worked with esteemed organizations such as Academisch Ziekenhuis Leiden and BioMarin Technologies B.V. Her career is marked by a commitment to advancing medical science and improving patient outcomes through innovative research and development.

Collaborations

Throughout her career, Annemieke has collaborated with notable colleagues, including Garrit-Jan Boudewijn Van Ommen and Judith Christina Theodora Van Deutekom. These collaborations have further enriched her research and contributed to her success in the field.

Conclusion

Annemieke Aartsma-Rus stands out as a leading inventor in the realm of muscle disorder therapies. Her innovative patents and dedication to research continue to pave the way for advancements in medical treatments.

Profile summary based on public USPTO records.